Johnson & Johnson names awardees in the Unlocking Urologic Oncology Innovation QuickFire Challenge

Today, at the AUA Innovation Nexus Forum in Washington, D.C., Johnson & Johnson together with the American Urological Association announced that Andromeda Surgical, Nanobots Therapeutics, and Tiller Therapeutics have been selected as the awardees of the Unlocking Urologic Oncology Innovation QuickFire Challenge.

Innovators from across the globe were invited to submit their transformative potential solutions to help improve treatment and care of patients with bladder and prostate cancers. These three awardees are being recognized for their potentially groundbreaking solutions aimed at reshaping the future of urologic cancer treatment:

The awardees will receive award funding from a total pool of up to $300,000 and mentorship from experts across Johnson & Johnson.*

_{*Subject to terms and conditions of applicable QuickFire Challenge and execution of an award agreement}

About Johnson & Johnson

Johnson & Johnson works across the innovative medicine and medical technology sectors to accelerate early-stage, transformational solutions by catalyzing the best ideas, wherever they are in the world. We do this by harnessing our deep scientific capabilities coupled with a wide range of tools, including customized deal structures, company creation, incubation and startup services, capital investments and other innovative business models that aim to meet the diverse needs of entrepreneurs, scientists, and emerging companies. Our goal is to help life science and health technology innovations thrive through collaboration and partnership with the global ecosystem, so that together we can change the trajectory of human health. Meet our passionate team of science and technology experts and learn how to collaborate with us at www.jnjinnovation.com.